With a new actionable target, we will begin to amour BAFF‐R CAR T cells with supportive molecules that can either ameliorate T‐cell exhaustion or combat the immunosuppressive tumor microenvironment associated with CLL. The gene discussed is TNFRSF13C; the disease is neoplasm.